Oravax's oral VLP vaccine in development targets three SARS CoV-2 virus surface proteins, including proteins less susceptible to mutation, thus making the vaccine potentially more effective against current and future variants of the Covid-19 virus
Collaboration to drive diagnostics exports, tap high-growth regional markets and build scalable commercialization platform
Approval marks Venus Remedies’ first anti-infective marketing authorization in Indonesia and enables the country’s first generic entry for this critical antibiotic combination
Venus Remedies now has 29 active product approvals in Vietnam alone
The approval marks Venus Remedies’ strategic entry into complex generics, expanding its injectable portfolio beyond traditional formulations
The authorization of bortezomib will enhance the company’s ability to deliver advanced cancer solutions in Southeast Asia
The company is making its mark through strategic initiatives, promising to become a significant presence in the evolving pharmaceutical sector
Venus Remedies' oncology wing has also secured marketing authorisation from Myanmar for another chemotherapy drug
The company has secured 506 marketing approvals for its oncology products across 76 countries.
With this, the number of marketing approvals for its oncology products across 75 countries has gone up to 503
Subscribe To Our Newsletter & Stay Updated
